Examination of burden of skeletal-related events in patients naive to denosumab and intravenous bisphosphonates therapy in bone metastases from solid tumors population.

CONCLUSIONS: Almost half (46.3%) of the treatment-naïve population with BM from ST experience SRE within 1-year of the first BM diagnosis. SRE was associated with an average $67,257 additional healthcare cost annually. Given the high SRE burden in these patients, early initiation of prophylactic therapy should be considered. PMID: 30286662 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research